Thermal build-up, decay and retention responses to local therapeutic application of 448 kHz capacitive resistive monopolar radiofrequency : A prospective randomised crossover study in healthy adults by Kumaran, Binoy & Watson, Tim
1 
 
Main title: Thermal build-up, decay and retention responses to local therapeutic 
application of 448 kilohertz Capacitive Resistive Monopolar Radiofrequency: A 
prospective randomised crossover study in healthy adults. 
Running title: Thermal effects of radiofrequency-based therapy. 
Authors: Binoy Kumaran & Tim Watson 
 
Affiliation of authors: Physiotherapy, Department of Allied Health Professions and 
Midwifery, School of Health and Social Work, University of Hertfordshire, Hatfield, AL10 
9AB, UK 
First author (corresponding author): Binoy Kumaran, Physiotherapy, Department of Allied 
Health Professions and Midwifery, School of Health and Social Work, University of 
Hertfordshire, Hatfield, AL10 9AB, UK. 
Tel: 01707 282395 
Email: b.r.kumaran@herts.ac.uk (email can be published) 
binoyphysio@gmail.com (email can be published) 
 
Second author: Professor Tim Watson, Physiotherapy, Department of Allied Health 
Professions and Midwifery, School of Health and Social Work, University of Hertfordshire, 
Hatfield, AL10 9AB, UK. 
Tel: 01707 284970 
Email: t.watson@herts.ac.uk 
 
 
2 
 
ABSTRACT 
Purpose: Radiofrequency-based electrophysical agents are widely used in therapy-related 
clinical practice for their thermal effects; mainly relieving pain and inflammation and 
improving tissue extensibility. The most commonly used and researched are shortwave 
therapies that operate at 27.12 megahertz. Although relatively new, electrophysical agents 
employing much lower frequencies have also emerged. Capacitive Resistive Monopolar 
Radiofrequency employing 448 kilohertz is one such therapy. This laboratory-based study 
aimed to investigate the skin thermal responses to 448 kilohertz radiofrequency-based 
therapy in healthy adults. 
Methods: In a two-group randomised crossover study, 15 volunteers attended two modes 
(Capacitive and Resistive) of 448 kilohertz radiofrequency-based therapy (using ‘Indiba 
Activ 902’) administered locally to the lower thigh region. Starting at minimum, the intensity 
was increased incrementally until thermal discomfort was felt. Participants reported three 
time points: thermal onset, definite thermal sensation and onset of thermal discomfort. Local 
skin temperature was measured before, immediately post and up to 45 minutes post-
treatment. 
Results: Both Capacitive and Resistive modes of therapy significantly increased the skin 
temperature and sustained it over the 45-minute follow-up. There was statistically significant 
difference between the thermal response patterns produced by the two modes. Peak post-
treatment temperatures attained were not significantly different between the two; however, 
the retention rate at follow-up was significantly higher for the Resistive mode. 
Conclusions: This study confirms that radiofrequency-based therapy at 448 kilohertz can 
significantly increase and sustain skin temperature. The study also provides useful baseline 
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data for further research in the low frequency ranges of radiofrequency-based therapy that 
remains largely unexplored. 
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INTRODUCTION 
Electrophysical agents (EPAs) are used by therapists to treat a wide variety of conditions. 
Some of these agents can induce hyperthermia in tissues without being invasive or ablative. 
While some produce superficial heating to the area of the body where the modality is applied 
[for example, infrared (IR) therapy], others such as radiofrequency electromagnetic field 
(RFEMF, or simply RF) based EPAs are capable of heating the skin as well as deeper 
structures (such as muscles and joint tissues) [1]. 
The physiological effects of heat on living tissues are well documented. Heat can induce 
changes in the superficial and deep tissues, at cellular and systemic levels. A modest rise in 
temperature (mild hyperthermia) is sufficient to accelerate and/or increase most cellular 
activity, and heat-induced vasodilatation can enhance local blood circulation in the tissues [1-
3]. Heat can also change the nature of connective tissues. It can alter the properties of tendon, 
ligaments and, to some extent muscle, by means of increasing the extensibility and reducing 
the tone and spasm [1-3]. The extent of physiological effect may vary depending on the level 
of exposure. 
In therapy, heat application is often used as a mode to relieve pain and inflammation and 
potentially enhance tissue healing. Various physiological mechanisms are believed to 
underpin the effects of heat on pain and tissue repair including but not limited to changes 
arising from an increase in the blood flow, oxygen uptake and chemical reaction rates. 
Therapeutically, a rise in tissue temperature by more than 1
o
C will help to relieve mild 
inflammation and an increase of 2–3oC will help to reduce pain and muscle spasm whereas an 
increase of 3–4oC can produce changes in tissue extensibility [3, 4]. Temperature rise of this 
range employed in therapy-related clinical practice is only ‘mild hyperthermia’ whilst in 
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many other invasive and cytotoxic procedures in medicine (e.g. – radiofrequency ablation) 
the rise is substantially higher. 
Radiofrequency-based EPAs have been employed for various levels of heat treatment in 
therapy practice since the early decades of last century [5]. The electromagnetic energy 
delivered by these devices generates heat in the tissues as a result of the oscillation and 
friction of charged molecules (such as proteins and ions). The rise in temperature itself is 
dependent upon the electrical properties of the tissues and the rate at which the energy is 
absorbed (Specific Absorption Rate, SAR) [1, 6]. 
Among the EPAs that are used to induce mild hyperthermia, Longwave diathermy (which 
employed RF fields of around 0.5–1 MHz) became obsolete in the 1950s; owing to practical 
limitations and the severe disturbances it caused to communication and broadcasting [7]. 
Shortwave therapy (SWT) (also known as shortwave diathermy, or SWD), which commonly 
operates at 27.12 MHz, and Microwave therapy (also known as microwave diathermy, or 
MWD), which operates at up to 2.45 GHz became more established in practice. However, 
microwave therapy is currently used infrequently in many countries [8, 9]. 
Shortwave therapy is used in two modes: continuous (CSWT) and pulsed (PSWT). CSWT 
has been widely used by clinicians since the 1930s but has now become less popular and 
infrequently used in the western world [8, 10]. Similar to microwave therapy, CSWT 
typically causes relatively higher levels of heating in the tissues compared to PSWT as it does 
not allow an adequate ‘thermal washout’ during the treatment [1]. The diminishing popularity 
of CSWT is linked partly to a ‘fashionable shift’ rather than solely to published evidence 
because an evidence base does exist in support of the use of CSWT [11]. By contrast, PSWT, 
which was developed in the 1940s, has since become the more popular delivery option and is 
still used widely [8, 10, 12]. 
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The majority of research on the biological effects of RF is centred on the higher frequency 
(microwaves); particularly areas such as mobile telephony [13]. However, a recent review of 
literature undertaken by the authors of this study [14] indicated that the RF currently used in 
therapy-related clinical practice is predominantly within the relatively lower frequency range 
of 30 kHz–30 MHz and largely limited to the shortwave range of 10–30 MHz (especially 
PSWT at 27.12 MHz as a delivery mode) [8, 10, 11]. 
Although the research is sparse, EPAs operating at significantly lower RF ranges (< 1 MHz) 
have also been reported and used in clinical practice to induce mild hyperthermia and other 
physiological effects [15-18]. An example for such EPAs currently used in therapy practice is 
Capacitive Resistive Monopolar Radiofrequency (CRMRF) that operates at a frequency of 
448 kHz. In this study, the authors aimed to investigate the skin thermal responses (thermal 
effects) to the cutaneous application of continuous mode CRMRF therapy in healthy adults. 
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MATERIALS AND METHODS 
Apparatus 
The CRMRF energy was delivered using the ‘Indiba Activ 902’ device (Indiba S. A., 
Barcelona, Spain). The equipment was factory calibrated and pretested for accuracy of 
output. The peak power of the device was 200 W [or 450 VA (Volt-Ampere)]. It delivers RF 
energy in two modes: Capacitive (CAP) and Resistive (RES), the intensity of which are given 
as percentage output. 
Rigid circular metallic electrodes with a diameter of 65 mm were used as active electrodes 
and a large flexible rectangular metallic plate (measuring 200 x 260 mm) was used as 
inactive electrode. A manufacturer supplied conductive cream was employed as a coupling 
medium between the electrode and the skin surface. The CAP electrode has a polyamide 
coating that acts as a dielectric medium, insulating its metallic body from the skin surface 
thus forming a capacitor with the treated tissues. The RES electrode is uncoated and passes 
RF energy directly through the body and in to the neutral plate. The RF intensity and the 
energy output (Figure 1) is shown on the machine display, which is also wirelessly recorded 
by a computer-based monitoring software programme in the research environment. A detailed 
log of the experimental data can be exported via the monitoring software. 
**Insert Figure 1 here** 
A hand-held contactless infra-red skin surface thermometer (Thermofocus 01500A3) and an 
infra-red tympanic thermometer (Braun ThermoScan IRT 4520) were used for skin surface 
and core temperature measurements respectively. The surface thermometer has a 
measurement accuracy of ±0.3 
o
C between 20.0–42.5 oC, with an improved accuracy of ±0.2 
o
C between 36.0–39.0 oC. The tympanic thermometer has a measurement accuracy of ±0.2 oC 
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between 35.5–42.0 oC, and ±0.3 oC outside of this range. A body composition monitor 
(Omron BF508) was used to obtain the weight, body fat percentage, visceral fat and the body 
mass index (BMI) measurements of the participants. An electronic metronome (Seiko) and a 
computer-based timer were used to provide one-second and 30-second beeps respectively in 
order to aid the experimental procedure. The room temperature and humidity were monitored 
using an electronic thermohygrometer (RS 212-124). 
Sample and groups 
A randomly selected cohort of 15 asymptomatic (self-reported) adults from among the 27,000 
staff and Students of the University of Hertfordshire, UK participated in the study. The 
recruitment was done through emails that were sent out university-wide. The respondents 
were screened for inclusion consecutively, and the first 15 eligible subjects were recruited 
(eligibility criteria explained below). All participants signed an informed consent prior to the 
study. The study was approved by the Health and Human Sciences Ethics Committee with 
Delegated Authority (HHSECDA) of the University of Hertfordshire (Protocol number: 
HSK/PG/UH/00015). 
Each participant attended two sessions; one each for the CAP and the RES modes thus 
forming two separate treatment groups. The order of attendance was randomised by 
concealment using a computer generated randomisation chart (IBM SPSS Statistics, Version 
20) and blinded from the participant. There were no control or placebo groups. Based on pilot 
experiments, a minimum gap of 48 hours was allowed between the two sessions so that no 
residual effects from the first session were present at the time of the second. Similar times (± 
one hour) of the day were chosen for either session for each participant. 
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Experimental procedure 
On the day of the tests, the participants were asked to avoid food, beverages and strenuous 
exercises within one hour before the start of the experiment to ensure that their physiological 
condition remained stable during the sessions. The participants were screened using an 
eligibility questionnaire including questions relating to any recent injury or illness and 
accepted contraindications to RF therapy (pregnancy, malignancy, metal or electronic 
implants in the body). Subsequently, their ‘skin thermal sensitivity’ was tested using test 
tubes filled with water at approximately three different temperatures (±0.5 
o
C): 45 
o
C (warm), 
35 
o
C (neutral) and 25 
o
C (cold). The participants were required to distinguish between the 
three temperatures in order to continue with their participation in the study. After this 
screening, demographic and anthropometric data were collected. 
To receive treatment, the participants were asked to lie down in supine position on a 
treatment plinth and were fully supported with pillows. A square area covering the lower one-
fourth of the anterior aspect of right thigh was marked with tape. The local skin temperature 
was recorded from the centre of the marked square area on the treated leg and the 
corresponding area of the untreated leg. The untreated leg served as a control. The core 
(tympanic) temperature was also concurrently monitored. The local skin temperature 
measurements were repeated every two minutes until it stabilised, which was then considered 
the baseline skin temperature. The neutral plate electrode was smeared with 20 ml of 
conductive cream and placed under the calf muscle belly, one-fourth way down the distance 
from the fibular head to the lateral malleolus of the treated leg. 
The CRMRF treatment was applied with the active electrode using 20 ml of cream in the 
marked square area. The intensity started at the lowest level permitted by the device and was 
raised by one level every 30 seconds. The active electrode produced firm circles on the skin, 
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at a rate of ‘one per second’ as guided by the metronome. The participants were instructed to 
report clearly and promptly at three time points: Firstly, when they start to feel heat on the 
skin (thermal onset), secondly, when they feel moderate yet comfortable heat (definite 
thermal sensation), and thirdly, when the heat starts to become uncomfortable (onset of 
thermal discomfort). All three time points and the corresponding treatment intensity were 
recorded. The treatment was stopped once the ‘onset of thermal discomfort’ was reached. 
After clearing the treated area, the post treatment (peak) skin temperature was recorded from 
either leg from the same spot used for the baseline measurement. The core temperature was 
also recorded at this time. The skin temperature measurements were repeated (follow-up) 
subsequently every 30 seconds on the treated leg and every five minutes on the control leg for 
the next 45 minutes, or till the temperature on the treated side returned to the baseline level 
(which ever was earlier). Core temperature, room temperature and humidity measurements 
were also repeated at the end of the experiment. 
**Insert Figure 2 here** 
In addition, a second brief experiment was conducted separately, to map the temperature 
changes in the active treatment electrodes at various stages of testing in response to set 
intensities (expressed as percentage) of application of the CRMRF energy. For this purpose 
three arbitrary intensity levels were chosen, alongside a fourth level, which would be the 
mean peak power reached during each mode of the main experiment. 
Data analysis 
All data was processed and analysed using Microsoft Office Excel (Version 2010, Microsoft 
Corporation) and IBM SPSS Statistics (Version 20) for Windows. The group data were 
compared using a two-way repeated measures analysis of variance (ANOVA) model with a 
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Bonferroni post-hoc comparison for the thermal responses of the CAP and RES modes at 
three time points (baseline, post treatment and 45-minute follow-up). The statistical 
significance was set at p≤0.05 (0.8P, 95%CI). 
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RESULTS 
All 15 participants completed both sessions of the study and the assessments as anticipated. 
The RF treatment was well tolerated and there were no reports of any adverse events that may 
be a consequence of the intervention, including any issues due to potential overheating. The 
demographic and the mean (±SD) anthropometric data from the participants are reported in 
Table I. 
The mean (±SD) skin thermal responses as well as individual thermal response patterns 
obtained from all 15 participants to both CAP and RES modes of CRMRF therapy are plotted 
in Figures 3a–b, 4a–b and 6a–b. The baseline, post treatment and 45-minute follow-up mean 
(±SD) skin temperatures obtained for the CAP mode were 30.9 (±1.1) 
o
C, 34.3 (±1.6) 
o
C and 
31.5 (±1.4) 
o
C respectively, and for the RES mode were 31.1 (±1.0) 
o
C, 35.0 (±1.2) 
o
C and 
33.2 (±1.4) 
o
C respectively. 
Table II shows the mean (±SD) time taken, energy delivered and the peak power output to 
reach each thermal stage. Figures 5a–c shows the individual data for the mean time, mean 
energy and mean peak power reported in Table II. 
There was no significant difference between the baseline skin temperatures of the two groups. 
Overall, there was statistically significant difference between the thermal response patterns 
produced by the CAP and RES modes [F (1, 14) = 16.639, p = 0.001] although their peak 
skin temperatures obtained at the end of treatment were not significantly different. From 
baseline to peak there was 11.1% increase in the mean skin temperature of CAP mode, and 
12.7% increase in that of RES mode.  
Both CAP and RES modes also showed a significant retention of the gained temperature at 
the 45-minute follow-up compared to their baseline [CAP: F (1, 14) = 8.690, p = 0.011; RES: 
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F (1, 14) = 70.321, p < 0.001]. However, the rate of temperature retention at the 45-minute 
follow-up was significantly higher for the RES mode compared to that of the CAP mode 
(53.6% and 17.5% retention respectively) [F (1, 14) = 36.173, p < 0.001]. 
No meaningful change was noted in the thermal response of either the untreated control side 
or the core (tympanic) temperature at any time point in either group. A post-hoc power 
analysis using G*Power (Version 3.1) confirmed the actual power of the obtained ANOVA 
results to be 1.0. 
The temperature changes recorded from the two active electrodes during the second 
experiment are reported in Table III. 
**Insert Table I here** 
**Insert Table II here**; **Insert Figures 5a, 5b & 5c here** 
**Insert Figures 3a, 3b, 4a, 4b, 6a & 6b here** 
**Insert Table III here** 
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DISCUSSION 
The literature surrounding the thermophysiological effects of RF on biological systems is 
extensive. Most of the published research in this area has been conducted on laboratory 
animals, the emphasis being particularly on rodents. It has been argued that these small 
mammals are poor models for human beings as their physiological heat loss mechanisms are 
limited thus making extrapolation of the results from such studies to human beings difficult 
[6]. For example, rodents (mice in particular) have a higher thermoneutral zone of around 30 
o
C whereas for humans (wearing clothes) it is 22–25 oC [19-21]. In the present experiment, 
the mean (±SD) room temperature was 24.0 (±0.8) 
o
C for the CAP mode and 23.9 (±1.2) 
o
C 
for the RES mode, both of which are within the thermoneutral zone of humans. 
Whether or not RF exposure to human body produces a thermal effect depends on many 
parameters of the wave; such as its frequency, intensity, duration of exposure and the area of 
body exposed. In a clinical environment, a prediction of this thermal response based on the 
existing models alone is challenging. Experimental and theoretical work suggests that at low 
intensity levels, ‘demodulation’ of RF is only practical at frequencies that are much lower 
than a few megahertz. In other words, the biological systems cannot ‘rectify’ RF fields above 
a few megahertz efficiently enough to affect the endogenous fields and the biological 
processes [13]. 
Radiofrequency waves may interact with the biological tissues through a number of 
mechanisms. While the theory underpinning the thermal effects of RF interaction is well 
established, arguably the claims about the ‘so called’ low level non-thermal (LLNT) effects 
are somewhat controversial and lack sufficient experimental support [13]. Although the non-
thermal interaction mechanisms may not be directly associated with a temperature rise in the 
tissues, thermal effects do occur even at very low levels because all interactions between the 
RF fields and the biological tissues will result in energy transfer to the tissues, ultimately 
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leading to an increase in temperature [22]. For example, cell metabolism can be affected by 
changes in temperature that are as small as a fraction of a degree [13]. However, as identified, 
many of the physiological benefits of heating occur when temperatures are raised by at least 2 
o
C. 
The extent of physiological effects induced by the heating modalities (EPAs) depends on the 
type of energy delivered by the EPA and its depth of penetration [23]. For example, it is 
believed that exposure to pulsed RF is more likely to induce certain biological effects than 
continuous RF at the same average incident pulse density. Similarly, while the low 
penetrative IR energy (non-RF) is absorbed in the most superficial layers of skin leading to 
superficial heating, RF frequencies will be absorbed in complex patterns at other depths [6], 
potentially causing deeper heating and hence deeper effects. Although not measured in this 
study, other researchers have reported that deep heating may be attained using RF-based 
EPAs, and is more effective in inducing certain physiological effects such as increasing tissue 
extensibility, compared to superficial heating [24, 25]. 
The results of the present study show significant differences between the patterns of heating 
produced by the CAP and RES modes of CRMRF therapy, as measured using a skin 
thermometer. The CAP mode response in relation to the three thermal stages (onset, definite 
and discomfort) was achieved considerably faster, but the built-up temperature decayed faster 
and was retained less compared to that of the RES mode. However, the lack of linearity 
between the intensity settings of the two modes renders any further comparison problematic. 
Similarly, the peak power achieved at each time point would also have been influenced by the 
lack of linearity. The individual data (Figure 4b) suggests that for either mode greater the 
temperature increase due to heating, the greater was the drop during the follow-up phase.  
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As stated, the mean (±SD) peak skin temperature obtained was 34.3 (±1.6) 
o
C for the CAP 
mode and 35.0 (±1.2) 
o
C for the RES mode (Figure 3a). The highest temperature recorded for 
any particular participant was 37.4 
o
C for the CAP mode and 37.0 
o
C for the RES mode 
(Figure 3b). Per se, these values are below or barely at the level of the core temperature. 
Hence, what is achieved is only ‘mild hyperthermia’ at best, and solely in relation to the 
baseline skin temperatures recorded at the treatment site. To be termed hyperthermia, the 
temperature will have to be raised to supra-physiological levels; that is to around 40–45 oC, 
or even higher for thermal ablation. As in vitro cell studies have shown, the cytotoxic effects 
of heat and cell death are prominent over a temperature range of 40–55 oC, with a ‘break 
point’ at around 43 oC [26-29]. 
A cumulative or equivalent thermal dose is often used to quantify the thermal doses given 
during heat treatments [30]. The cumulative or total equivalent thermal dose can be expressed 
as Cumulative Equivalent Minutes (CEM) in relation to the arbitrarily chosen temperature of 
43 
o
C (CEM 43), as originally proposed by Sapareto and Dewey [31]. Using this method any 
‘time–temperature’ history can be converted to a single number that represents a ‘thermal 
isoeffect dose’, which is an equivalent number of minutes of heating at 43 °C. The following 
formula is used for this calculation if the temperature remained constant:  
CEM 43 
o
C = tR
(43-T)
 
Where ‘CEM 43 °C’ is the cumulative number of equivalent minutes at 43 °C, ‘t’ is the time 
(duration) of treatment, ‘R’ is a constant related to the temperature dependence of the rate of 
cell death [R (T< 43 °C) = 0.25, R (T>43 °C) = 0.5] and ‘T’ is the temperature during ‘t’. 
For a complex time-temperature history, the CEM 43 °C is calculated for each small time 
interval (t) where the temperature (T) has remained relatively constant and summated over 
the entire period using the formula: 
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CEM 43 
oC = ∑tR(43-Tavg) 
Where ‘Tavg’ is the average temperature for each time interval (t). The resulting CEM 43 °C 
value represents the effect of the entire history of heat exposure. 
Estimates of ‘thermal isoeffect dose’ are predominantly used in the dosimetry of cancer 
thermotherapy and of magnetic resonance (MR) systems [30]. It can also be performed for 
CRMRF therapy, since studies employing CRMRF to induce hyperthermia for cancer [18, 
32-34] and other cellular effects [17] have been reported. 
In the present study, only the baseline and peak temperatures were measured while RF was 
applied. If an assumption is made that the peak temperature attained was maintained for the 
total duration of treatment for each participant, the mean (±SD) CEM 43 °C thermal dose for 
the sample can be calculated to be 0.0004 (±0.0008) minutes for the CAP mode and 0.0005 
(±0.0008) minutes for the RES mode. However, this calculation is only applicable to the area 
of skin from where the temperature measurements were taken. No such estimation can be 
given using the current data for the deeper tissues, where the thermal dose might have been 
completely different. 
The peak powers reported in ‘Table II’ and ‘Figure 5c’ do not necessarily provide an accurate 
reflection of the CRMRF powers required to achieve the three time points in a normal 
treatment session where a set treatment dose may be delivered from the beginning. Rather, 
they denote the peak powers that may be achieved if the intensity is incrementally raised 
every 30 seconds starting at the minimum dose. The mean (±SD) of mean powers (MP) (the 
‘mean overall power’ provided for each participant for the duration of the treatment) 
delivered to reach the thermal onset, definite thermal and thermal discomfort stages were 
3.89 (±0.99), 6.05 (±1.36) and 11.70 (±1.67) Watts respectively for the CAP mode and 10.61 
(±3.78), 17.87 (±5.36) and 28.74 (±4.74) Watts respectively for the RES mode. 
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The skin temperatures at the thermal onset and definite thermal stages were not recorded, as 
this would have affected the continuity of treatment and have delayed the attainment of the 
subsequent thermal stage due to a ‘thermal washout’. The peak skin temperatures attained 
were not significantly different between the two modes despite the non-linearity of their 
intensity settings. However, while the CAP mode showed a sharp decline in the (mean) skin 
temperature in the immediate post treatment phase, by contrast the RES mode (mean) skin 
temperature showed an increase in the first few minutes after the treatment ended. These 
dissimilar thermal output patterns are unlikely to have been influenced by the intensity 
settings. 
More than 60% of the gained heat [Mean (±SD) of 60.3 (±34.5) %] has been retained in the 
RES mode at the end of the 45-minute follow-up, as against 15% [Mean (±SD) of 15.5 
(±20.1) %] in the CAP mode (Figure 4a). The untreated control side and the core 
temperatures did not change significantly at any point for either condition. While it was 
unsurprising that the core temperature did not change since a local application of RF energy 
is not expected to influence the core temperature [6], the results of the control leg is contrary 
to the ‘crosstalk’ effect (undesirable effect generated in the neighbouring untreated area) that 
has been reported in SWT research [35]. This may be due to potentially lower levels of 
‘scattering’ of the waves from CRMRF therapy compared to SWT. 
The faster heating and faster thermal decay associated with the CAP mode CRMRF may be 
indicative of its relatively superficial nature of penetration. Similar to the ‘capacitive method’ 
of application in SWT, there may be a higher proportion of ‘electric’ (E) than ‘magnetic’ (H) 
field causing a capacitive (faradic) effect in the tissues [4, 11]. Proportionally, more energy is 
absorbed in the superficial tissues (such as the skin and fat layers) than in the deeper tissues 
(underlying tissues such as muscles) as there is a higher concentration of field in the 
superficial tissues [36, 37].  
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Similarly, the RES mode CRMRF is comparable to the ‘inductive method’ in SWT as they 
both generate an effect that is predominantly due to an H field [4, 11]. The higher retention of 
heat and the fact that there was no sharp fall in the post-treatment temperature strongly 
suggests higher energy penetration. While the energy absorption for inductive treatment is 
greater in deeper tissues such as blood and muscles due to their lower resistance and higher 
electrolyte content, tissues such as skin and subcutaneous fat that have higher resistance 
absorb less energy and therefore heat up less compared to the deeper tissues [11, 37]. 
The amount of heat generated is proportional to the conductivity of the tissues and the 
strength of the field [4]. Penetration by the RF energy is also influenced by the size of 
treatment electrodes; with the larger electrodes having more penetrative ability than the 
smaller electrodes [11]. There is a fundamental difference between SWT and CRMRF when 
the frequency and other characteristics of their RF waves are considered, hence, all the 
physical principles of shortwave-tissue interaction may not apply to CRMRF. When 
compared to SWT, there is little published research on the physical principles of CRMRF-
tissue interaction. 
The results obtained here are likely to have been influenced by the size (large; 65 mm in 
diameter) and geometry (circular) of the active electrodes used, the amount of conductive 
cream left on the skin, and other individual factors such as anatomy of the area treated, tissue 
resistance and potentially the anthropometric factors (e.g. – body fat percentage, body mass 
index). However, the crossover study design would have mitigated the influence of such 
individual factors on the results. 
The electrode size used was appropriate for the size of the area treated, potentially helping the 
homogeneity of field distribution. The size of electrode influences the magnitude of 
electromagnetic field generated and the field/current density [11]. With large electrodes the 
20 
 
field density would not have been disproportionately high under the active electrode thus 
ensuring a more even distribution of energy. The research surrounding the field/current 
density is a separate area in itself, which was not aimed to be analysed in the present study. 
As reported in Table III, the temperature of the electrodes at similar intensities of CRMRF 
application as in the main experiment was not significantly different from the peak skin 
temperature reached. The peak RES mode electrode temperature remained consistently lower 
than that of the skin, while the CAP mode electrode temperature increased marginally when 
the intensity of exposure was sustained for longer periods. This suggests that the rise in skin 
temperature was not a direct result of contact heating from a hot electrode, but rather due to 
RF-tissue interaction. 
The participants generally reported a more superficial ‘feel’ for heating in the CAP mode, 
with the heating reported mainly on the skin of the treated area. Little heat was reported 
through the knee joint or into the calf. However, the ‘feel’ was reported to be deeper and 
more homogenous with the RES mode, with the knee joint and calf involved. 
However, the claims about perception of heat at depth should be interpreted with caution, 
because localised thermal perception is based primarily on cutaneous receptors [2] and there 
remains some controversy as to whether thermal perception at depth is thermal perception per 
se or nociception. To date there is insufficient evidence on the existence of subjective 
perception of temperature from deeper tissues such as muscle [38]. There may be a 
mechanism of thermal perception at depth, but it may be at a subconscious level when tissue 
temperature is approximately between 25–41 oC. Thermal perception in muscle beyond this 
level is arguably less potent compared to nociception. Question also remains as to whether 
the nociceptors and other pressure and mechanosensitive receptors in the muscle might also 
function as peripheral sensors for subjective temperature sensation in humans [38, 39]. 
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The sensation of heat in the tissues depends on the pattern of thermal energy delivery (e.g. – 
thermal change, rate of thermal change) [1, 2, 6]. For the above reasons, it is therefore 
proposed that although deep heating may have occurred from the CRMRF therapy, the 
different heating sensations reported from the CAP and RES modes by the participants in this 
study may relate to a variation in the rate and distribution of temperature change in the more 
superficial tissues such as the skin and superficial fascia, where there is a presence of 
thermoreceptors. 
In this study, any potential variability in the thermal response data between individual 
participants may be explained by the variability in their anthropometric factors. Although it 
was not the primary aim of the study, the correlation between the anthropometric factors and 
the thermal responses were analysed in order to assess if a prediction of one’s thermal 
response is possible from their anthropometric and baseline data using a statistical (linear 
regression) model. 
The body fat percentage appeared to have a moderate negative correlation (significant at 
p<0.05 level) with the CAP thermal onset and discomfort data, whereas the same was 
observed only for the thermal discomfort data in the RES mode. A moderate negative 
correlation (significant at p<0.05 level) was also observed between the room temperature and 
the RES mode thermal onset and definite thermal data. No other anthropometric factors 
correlated with the thermal response data. Hence, an appropriate statistical model for the 
prediction of one’s thermal response and treatment doses could not be determined for either 
mode of treatment using the data in this study. 
To our knowledge, this is the first study investigating the skin thermal responses to local 
therapeutic application of RF below the shortwave frequencies. Several studies investigating 
the skin and/or deep thermal responses of humans resulting from exposure to RF 
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(predominantly the shortwave frequencies) have been identified [35, 40-47], although only a 
limited number of those studies have mapped skin temperature for as long as 45 minutes post 
treatment. A significant rise and maintenance of both skin and intra-muscular temperatures 
were reported by many of the earlier published studies [40, 42, 43, 47]. 
Among the more recent (non-invasive) studies, Bricknell et al. [41] that employed 
incremental doses of PSWT reported their dose parameters that produced a ‘possible thermal 
perception’ [Mean ‘mean power (MP)’ of 6.58 (±3.50) W] and a ‘definite thermal perception’ 
[Mean MP 10.88 (±3.32) W] on the skin. A mean temperature increase of 2.10 
o
C from 
baseline to the definite thermal stage was reported. In another study, Al-Mandeel et al. [35] 
reported a significant rise in the skin temperature with high (MP 24 W) and low (MP 3 W) 
doses of PSWT. 
Among the invasive studies, Draper et al. [44] investigated the temperature changes inside 
the gastrocnemius muscle in response to a 20-minute treatment with PSWT (MP 48 W). A 
mean (±SD) temperature rise of 3.49 (±1.13) 
o
C was reported after the treatment and a decay 
of 1.78 (±0.69) 
o
C was reported in the first 10 minutes post-treatment. Later, in a non-
shortwave study, Takahashi et al. [45] reported a 5 
o
C rise in temperature inside the knee joint 
with a 20-minute pulsed RF (8 MHz, 200 W) treatment on patients suffering from 
osteoarthritis of the knee. The temperature decay was not monitored in this study. 
A potential limitation of the current study is that it was unable to investigate the temperature 
changes at depth, despite it being evident from the results that considerable absorption of heat 
may have occurred in the deeper tissues. While appropriate non-invasive methods for 
temperature measurement at depth were not available to the authors, several potential issues 
exist with invasive temperature measurements. For example, where the temperature recording 
device (thermocouples or thermistors) was left in situ while the RF was delivered (as in the 
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study by Takahashi et al. [45]), it is highly likely that the electromagnetic field might have 
directly heated the measurement device thus showing a higher temperature recording. 
Furthermore, the invasive procedure triggers a tissue inflammatory response, which 
potentially affects the local physiological activity (such as a change in the local blood flow). 
Non-invasive temperature measurement at depth using techniques such as magnetic 
resonance (MR thermometry) and ultrasound (US thermometry) are gaining ground and are 
employed in areas like cancer thermotherapy [48-51]. Such techniques are far more complex 
and were beyond the scope of this study. Nonetheless, similar studies employing such 
comprehensive non-invasive measurement systems to investigate the thermal effects of 
CRMRF based treatment in deeper tissues should be welcomed in the future. 
In addition to deep temperature, the skin temperature at the thermal onset and definite 
thermal stages were also not recorded in this study. Considering the methodology that was 
adopted in this experiment, it would have been difficult to record those temperatures without 
significantly affecting the continuity of treatment. 
Likewise, the thermal response patterns reported here may only be applied to the size of 
active electrodes (65 mm) used in this experiment owing to the considerations on electric 
field density; and the body area treated owing to anatomical considerations. The thermal 
properties of the conductive cream and the amount of cream left on the treated area towards 
the end of treatment also would have influenced the attainment of thermal stages. 
A further limitation commonly found in laboratory studies is that the participants may be 
young and physically fit subjects, limiting the generalizability of the results. In this study, 
although the participants were physically fit and active; their age range (19–59 years) was 
purposefully kept wide to improve generalizability. In any case, extrapolation of these results 
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to a patient population is problematic as their physiological responses will be different due to 
the underlying pathology. 
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CONCLUSIONS 
This study confirms that both the CAP and the RES modes of CRMRF therapy can 
significantly increase and sustain skin temperature. Average time, energy and power required 
to achieve thermal onset, definite thermal and thermal discomfort sensations when the doses 
were delivered incrementally (as described), were identified for both modes of treatment. 
This study did not aim to provide recommendations on dosing based on perceived heat, and 
per se, the results cannot be extrapolated to a patient population. However, they may provide 
guidance to clinicians for clinical decision making when they decide to use such therapy. The 
study also provides useful baseline data for further research in the low frequency ranges of 
RF therapy that has remained largely unexplored. Further studies that address the limitations 
of this study and explore additional physiological responses (such as blood flow, temperature 
at depth), and clinical studies that involve patient groups are therefore necessary. 
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Table I: Demographic and mean (±SD) anthropometric data from the 15 participants 
who received localised 448 kHz Capacitive Resistive Monopolar Radiofrequency 
(CRMRF) treatment. 
 
Number 
Demographic data Mean (±SD) anthropometric data 
Mean 
(±SD) age 
(years) 
Gender: 
Males 
Gender: 
Females 
Height 
(m) 
Weight 
(kg) 
Body fat 
(%) 
Visceral 
fat 
BMI 
15 
45.1 
(11.6) 
6 9 
1.7 
(0.1) 
73.1 
(13.1) 
32.3 
(8.3) 
7.6 
(3.4) 
25.6 
(3.8) 
 
SD – standard deviation; kg – kilogram; m – metre; BMI – body mass index. 
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Table II: Mean time, mean energy and mean peak power reached at each of the three 
thermal stages for 15 participants who received localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment. 
 
Stage 
CAP Mode RES Mode 
Mean (±SD) 
time (s) 
Mean (±SD) 
energy (J) 
Mean 
(±SD) peak 
power (W) 
Mean (±SD) 
time  (s) 
Mean (±SD) 
energy (J) 
Mean 
(±SD) peak 
power (W) 
Thermal 
onset 
159.1 
(55.2) 
664.7 
(405.2) 
6.1 
(2.3) 
285.5 
(109.9) 
3417.3 
(2299.9) 
21.3 
(9.6) 
Definite 
thermal 
261.5 
(56.9) 
1635.1 
(635.3) 
13.2 
(3.5) 
463.9 
(116.2) 
8867.6 
(4531.4) 
42.5 
(16.9) 
Thermal 
discomfort 
399.7 
(70.2) 
4764.0 
(1467.6) 
32.4 
(11.8) 
656.0 
(64.4) 
19137.5 
(5087) 
81.5 
(20.1) 
 
SD – standard deviation; J – joules; W – watts; s – seconds 
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Table III: Electrode (active) temperature at various times and intensity of application 
during localised 448 kHz Capacitive Resistive Monopolar Radiofrequency (CRMRF) 
treatment. 
The study was conducted on a single male participant, aged 37 years (Body Mass Index, 
23) at room temperature 25 
o
C and humidity 66%. 
 
CAP Mode Temperature (
o
C) RES Mode Temperature (
o
C) 
Intensity in 
percentage 
(device PP is 
450 VA) 
At three 
minutes 
At six 
minutes 
At nine 
minutes 
Intensity in 
percentage 
(device PP is 
200 W) 
At three 
minutes 
At six 
minutes 
At nine 
minutes 
19 30.2 31.4 31.7 11 27.9 28.1 28.6 
31 31 32.5 33.2 22 29.4 30.3 30.7 
40 33.4 34.3* 36.2* 32 30.9 30.9* 32.8* 
67
#
 35.7** XX XX 40
# 
32.8** XX XX 
 
PP – peak power; VA – volt-ampere; W – watts; oC – degree Celsius; XX – not measured due 
to thermal discomfort to the participant. 
# Denotes the mean peak power obtained from 15 participants during the CAP and RES 
modes of the main experiment. 
* Moderate heating reported by the participant. 
** High heating reported by the participant. 
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Figure 1: Graphs showing the output data as obtained from the device monitoring software. The data shown are from one participant 
(Number 8). The X-axis shows the monitoring sequence units (more than one per second) and the Y-axis shows the parameter recorded. 
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Figure 2: The experimental setting with the 448 kHz Capacitive Resistive Monopolar Radiofrequency (CRMRF) device (Indiba Activ 
902, Indiba S. A., Barcelona, Spain), electrodes and the computer-based monitoring software. 
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Figure 3a: Capacitive (CAP) and Resistive (RES) mode mean skin thermal responses to localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment. 
The data shown (baseline, post treatment and 45-minute follow-up) are from 15 participants. Statistically significant differences when 
compared to the baseline (at p<0.05) are indicated by asterisks (*) above the error bars (two-way repeated measures ANOVA). 
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Figure 3b: Capacitive (CAP) and Resistive (RES) mode individual skin thermal responses to localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment (treated side only). 
The data shown (baseline, post treatment and 45-minute follow-up) are from 15 participants. 
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Figure 4a: Capacitive (CAP) and Resistive (RES) mode mean skin thermal changes after localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment (treated side). 
The data shown (thermal build-up, thermal decay and thermal retention) are the changes in relation to the baseline from 15 
participants. Statistically significant differences when compared to the baseline (at p<0.05) are indicated by asterisks (*) above the error 
bars (two-way repeated measures ANOVA). 
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Figure 4b: Capacitive (CAP) and Resistive (RES) mode individual skin thermal changes after localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment (treated side). 
The data shown (thermal build-up, thermal decay and thermal retention) are the changes in relation to the baseline from 15 
participants. 
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Figure 5a: Capacitive (CAP) and Resistive (RES) mode time-specific individual skin thermal responses to localised 448 kHz Capacitive 
Resistive Monopolar Radiofrequency (CRMRF) treatment (treated side only). 
The data shown (thermal onset, definite thermal and thermal discomfort) are from 15 participants. 
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Figure 5b: Capacitive (CAP) and Resistive (RES) mode energy-specific individual skin thermal responses to localised 448 kHz 
Capacitive Resistive Monopolar Radiofrequency (CRMRF) treatment (treated side only). 
The data shown (thermal onset, definite thermal and thermal discomfort) are from 15 participants. 
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Figure 5c: Capacitive (CAP) and Resistive (RES) mode power (peak)-specific individual skin thermal responses to localised 448 kHz 
Capacitive Resistive Monopolar Radiofrequency (CRMRF) treatment (treated side only). 
The data shown (thermal onset, definite thermal and thermal discomfort) are from 15 participants. 
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Figure 6a: Capacitive (CAP) and Resistive (RES) mode mean skin thermal decay after localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment (treated side). 
The data are from 15 participants, showing the decay process from post treatment to 45-minute follow-up. 
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Figure 6b: Capacitive (CAP) and Resistive (RES) mode individual skin thermal decay after localised 448 kHz Capacitive Resistive 
Monopolar Radiofrequency (CRMRF) treatment (treated side). 
The data are from 15 participants, showing the decay process from post treatment to 45-minute follow-up. 
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